Format

Send to

Choose Destination
Cancer. 2019 Mar 2. doi: 10.1002/cncr.31996. [Epub ahead of print]

A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.

Author information

1
Department of Hematology and Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.

KEYWORDS:

NSCLC; PACIFIC trial; durvalumab; immune checkpoint inhibition; stage III NSCLC

PMID:
30825394
DOI:
10.1002/cncr.31996

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center